Skip to main content

Table 2 Main clinical laboratory values of COVID-19 follow-up patients

From: Follow-up study on serum cholesterol profiles and potential sequelae in recovered COVID-19 patients

Laboratory values

Reference ranges

COVID-19 follow-up patients

Mild (n = 59)

Severe/Critical (n = 48)

Adm

Flw

p

Adm

Flw

p

LDL-c

*109 (29) mg/dL

100.5 (87.0, 113.3)

103.6 (90.5, 116.0)

0.048

96.1 (74.3, 107.2)

103.6 (76.2, 123.4)

0.003

HDL-c

*52 (15) mg/dL

52.9 (46.0, 64.2)

54.5 (46.8, 63.4)

0.297

50.3 (43.7, 65.4)

55.3 (46.0, 65.7)

0.042

TC

*182 (34) mg/dL

197.9 (170.5, 223.5)

203.4 (187.2, 220.8)

0.042

192.4 (151.3, 221.6)

203.2 (152.1, 246.6)

0.016

Non-HDL-c

*130 (35) mg/dL

144.2 (118.3, 160.8)

147.0 (125.3, 165.9)

0.039

135.7 (102.8, 157.4)

151.8 (103.7, 182.4)

0.009

TG

*133 (99) mg/dL

165.5 (131.1, 219.6)

140.8 (108.1, 177.1)

0.001

141.7 (107.6, 182.2)

143.9 (111.6, 200.6)

0.376

WBC

3.5–9.5 (×109/L)

5.8 (5.2, 6.8)

5.4 (4.7, 6.2)

0.002

6.3 (5.0, 8.1)

5.6 (5.0, 6.7)

0.046

LY

*2.1 (0.5) (× 109/L)

1.5 (1.3, 1.8)

1.9 (1.5, 2.2)

<  0.001

1.6 (1.1, 1.9)

2.0 (1.5, 2.3)

<  0.001

MO

0.1–0.6 (×109/L)

0.5 (0.3, 0.6)

0.3 (0.2, 0.4)

<  0.001

0.5 (0.3, 0.7)

0.3 (0.3, 0.4)

<  0.001

D-dimer

<  0.5 mg/ml

0.5 (0.2, 0.8)

0.3 (0.2, 0.4)

<  0.001

0.7 (0.4, 1.1)

0.4 (0.3, 0.5)

<  0.001

ATIII

80–120%

90 (81.5, 96.5)

97 (89, 102.5)

<  0.001

88 (81.2, 93.8)

96 (87, 102.8)

0.001

FDP

<  5 μg/L

1.7 (1.1, 2.5)

1.1 (1, 1.5)

<  0.001

2.7 (1.6, 3.7)

1.3 (1.0, 2.0)

<  0.001

FIB

2–4 g/L

4.0 (3.4, 5.2)

3.2 (2.7, 3.5)

<  0.001

4.6 (3.7, 5.5)

3.3 (3.0, 3.7)

<  0.001

CRP

<  4 mg/L

1.7 (0.6, 4.8)

1.4 (0.6, 2.2)

<  0.001

2.9 (1.2, 8.3)

1.6 (1.1, 2.6)

0.002

ALT

5–35 U/L

36 (22, 54)

25 (19, 32)

<  0.001

33.5 (21.8, 62.2)

21 (15, 32.4)

0.013

ALP

40–150 U/L

89 (72, 104)

77 (64, 87)

<  0.001

91 (71, 107)

73 (64, 85)

<  0.001

GGT

7–32 U/L

32 (22, 51)

23 (17, 32)

<  0.001

31.5 (18.7, 50.5)

23 (18, 31)

<  0.001

TBIL

5.1–19 μmol/L

11.5 (9.8, 14.6)

16.7 (12.2, 20.8)

<  0.001

11.1 (8.8, 14.3)

13.2 (10.8, 15.9)

0.002

DBIL

1.7–6.8 μmol/L

3.1 (2.5, 3.6)

3.7 (3, 4.5)

<  0.001

3.2 (2.4, 4.0)

3.2 (3, 3.7)

0.215

TBA

0–10 μmol/L

4.3 (3.2, 6.9)

2.5 (1.5, 3.7)

<  0.001

4.7 (3.3, 7.7)

2.6 (1.3, 4.6)

<  0.001

TP

64–83 g/L

70.6 (67.6, 74.7)

73.8 (71.9, 77.2)

<  0.001

68.9 (65.4, 72.3)

75.4 (72.8, 79.5)

<  0.001

GLB

20–30 g/L

28.6 (26.4, 31.7)

27.4 (24.7, 29.7)

0.002

28.9 (26.4, 32.6)

29.0 (25.5, 31.8)

0.506

ALB

35–55 g/L

41.9 (39.4, 44)

46.8 (45.7, 49)

<  0.001

37.4 (6.4)

46.5 (2.7)

<  0.001

A/G ratio

1.5–2.5

1.5 (1.3, 1.6)

1. 7 (1.5, 1.9)

<  0.001

1.3 (1.2, 1.5)

1.6 (1.5, 1.8)

<  0.001

  1. *Data are adapted from age and gender-matched normal subjects from the city of Wuhan [11]. Data are presented as mean (SD) in reference ranges or median (IQR) unless stated otherwise. A Wilcoxon signed-rank test (two-sided) is used to compare variables at the times of admission with follow-up from the same subjects within groups (mild and severe/critical cases)
  2. Adm at time of admission, Flw follow-up, ATIII antithrombin III, FDP fibrin degradation product, FIB fibrinogen, ALT alanine aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyl transferase, WBC white blood cell, LY lymphocyte, MO monocyte, TC total cholesterol, TG triglycerides, TP total protein, ALB albumin, GLB globulin, TBIL total bilirubin, DBIL direct bilirubin, CRP C-reactive protein, TBA total bile acid, A/G ALB/GLB ratio
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us